stockrowOrganon & Co.
OGNHealthcare Drug Manufacturers General
Organon & Co.’s revenue for fiscal 2025 (year ended December 2025) was $6.2 billion, down 2.92% from fiscal 2024.
- Revenue
- −1.75%
- EPS
- +1.64%
- Free cash flow
- +118.8%
- Total debt
- −3.10%
Quarter to September 2026, against a year earlier
Follow OGN
Alert me
Organon & Co. (OGN) Return on invested capital
Organon & Co.'s return on invested capital over the twelve months to 30 September 2026 was 6.26%, up 0.4 percentage points from fiscal 2025 (5.84%). Over the past ten years it has ranged from 0.00% (fiscal 2018) to 33.8% (fiscal 2019); the current reading is higher than 25% of that period. That is in line with the Drug Manufacturers General industry median of 6.26% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 5.84% | (4.06) |
| FY2024 | 9.90% | 0.08 |
| FY2023 | 9.82% | (3.59) |
| FY2022 | 13.4% | (2.84) |
| FY2021 | 16.3% | (15.49) |
| FY2020 | 31.7% | (2.06) |
| FY2019 | 33.8% | 33.80 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 29.6% |
| BMY Bristol Myers Squibb Company compare | 13.2% |
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| SNY Sanofi compare | 7.05% |
| OGN Organon & Co. | 6.26% |
| PFE Pfizer Inc. compare | 6.19% |
| GRFS Grifols, S.A. compare | 4.76% |
| BIIB Biogen Inc. compare | 1.94% |
| AMRN Amarin Corporation PLC compare | −16.6% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on OGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement